Michael Andrew Chambers, Director at Sarepta Therapeutics, Inc. (SRPT), bought 19,958 shares at $109.89 ($2.2M) on 2023-08-14, disclosed to the SEC on 2023-08-15.
Open-market purchase of $2.2M SRPT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $109.19 | 5,947 | $649K | 29.7% |
| 2 | $109.19 | 5,947 | $649K | 29.7% |
| 3 | $109.89 | 4,032 | $443K | 20.3% |
| 4 | $109.89 | 4,032 | $443K | 20.3% |
| Total | $109.47 avg | 19,958 | $2.2M | 100% |
| Filing → |
| SRPT | BUY | 2023-08-11 | $7.4M | — | Filing → |
| SRPT | BUY | 2022-09-15 | $11.3M | — | Filing → |
| SRPT | BUY | 2022-08-22 | $5.0M | — | Filing → |